First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients

Abstract

In conclusion, the SVR rates in our study were lower than those reported in pre-marketing studies but were comparable to real-life data. ADRs, particularly hematological ADRs, were more common compared to those in previous studies and resulted in a high rate of treatment discontinuity.

Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C

“…The incorporation of TT for the treatment of CHC had an ICER value that exceeded by three times the GDP per capita value for all scenarios, considering the variation of effectiveness and minimum, maximum and mean costs. Considering that this threshold is overestimated for Brazil, the reality becomes even worse 11,28 .…”

“…This is a cost-effectiveness analysis from the perspective of a public health system. This analysis was proposed as part of a real-life study performed at the General Hospital of the Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil (HCFMRP-USP, in Portuguese), which included patients chronically infected with HCV genotype 1 11 . The main effectiveness and clinical data of this study are presented in Supplementary Table 1 (http://cadernos.ensp.fiocruz.br/ site/public_site/arquivo/suppl-e00036619_6733.pdf).…”